...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of hepato-biliary-pancreatic surgery >Prognostic factors for long-term survival in patients with locally invasive pancreatic cancer.
【24h】

Prognostic factors for long-term survival in patients with locally invasive pancreatic cancer.

机译：局部浸润性胰腺癌患者长期生存的预后因素。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND/PURPOSE: We aimed to investigate predictors of survival in patients with resectable locally invasive pancreatic cancer. METHODS: The patient cohort consisted of 55 patients with locally invasive pancreatic cancer (International Union Against Cancer [UICC] stage III in 36 patients and stage IV in 19) who had undergone resection. The patients were informed about the advantages and the adverse effects of postoperative chemotherapy, and prospectively selected either observation alone or postoperative chemotherapy. The postoperative chemotherapy regimen options were: (1) intraarterial chemotherapy alone, (2) systemic chemotherapy alone, or (3) intraarterial chemotherapy combined with systemic chemotherapy. RESULTS: Overall 1-year and 2-year survival rates after resection were 40.5% and 13.5%, respectively. Median survival time was 10.9 months. Twenty-nine patients (52.7%) received postoperative chemotherapy. On univariate analysis, only postoperative chemotherapy was associated with long-term survival (P < 0.01). In the patients with postoperative chemotherapy, the 1-year survival rate and MST were 61.7% and 16.3 months, compared with 20.1% and 7.9 months in the patients without postoperative chemotherapy. Multivariate analysis also showed that only postoperative chemotherapy was identified as an independent survival factor. CONCLUSIONS: It was suggested that postoperative chemotherapy was essential for the improvement of survival in patients with locally invasive pancreatic cancer.
机译：背景/目的：我们旨在研究可切除的局部浸润性胰腺癌患者的生存预测因子。方法：该患者队列包括55例接受了切除术的局部浸润性胰腺癌（国际抗癌联盟（UICC）III期36例，IV期19例）。告知患者术后化疗的优缺点，并前瞻性选择单独观察或术后化疗。术后化疗方案的选择是：（1）单纯动脉内化疗，（2）单纯全身化疗，或（3）动脉内化疗联合全身化疗。结果：切除后1年和2年总生存率分别为40.5％和13.5％。中位生存时间为10.9个月。二十九例患者（52.7％）接受了术后化疗。在单因素分析中，只有术后化疗与长期生存相关（P <0.01）。术后化疗患者的1年生存率和MST分别为61.7％和16.3个月，而未进行术后化疗的患者为20.1％和7.9个月。多变量分析还显示，只有术后化疗才被确定为独立的生存因素。结论：建议术后化疗对于改善局部浸润性胰腺癌患者的生存至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号